Colorectal Cancer: Epidemiology, Molecular Pathogenesis, and Emerging Therapeutic Innovations

Abstract

One of the most common cancers in the world, colorectal cancer (CRC) poses a serious threat to global health. This review provides a comprehensive overview of colorectal cancer, encompassing epidemiology, molecular pathogenesis, risk factors, screening strategies, diagnostic approaches, staging systems, treatment modalities, and emerging therapeutic innovations. CRC remains a major cause of cancer-related death despite improvements in screening and treatment. Developing successful preventative measures and individualized treatment plans requires an understanding of the intricate interactions between genetic, environmental, and lifestyle factors. The treatment of colorectal cancer has been transformed by recent advancements in molecular profiling, immunotherapy, and targeted therapies, which have given rise to fresh optimism for better patient outcomes.

Keywords

Colorectal cancer, adenocarcinoma, screening, molecular pathways, microsatellite instability, targeted therapy, immunotherapy, surgical oncology, adjuvant chemotherapy, precision medicine

Introduction

Colorectal cancer represents malignant transformation of the epithelial cells lining the colon or rectum. It is the second most common cause of cancer-related deaths globally and the third most common type of cancer diagnosed. A well-defined adenoma-carcinoma sequence is usually followed in the development of colorectal cancer (CRC), which progresses over years to decades from normal mucosa through adenomatous polyps to invasive carcinoma. (2) This relatively long developmental timeline provides opportunities for early detection and prevention through screening programs. Geographically, the burden of colorectal cancer varies greatly; developed countries have higher incidence rates, but rates in developing countries are rapidly increasing as a result of westernizing lifestyles. (3) Understanding the multifaceted nature of CRC—from molecular mechanisms to clinical management—is essential for oncologists, gastroenterologists, surgeons, and primary care physicians involved in cancer care.

2. Epidemiology

2.1 Worldwide Mortality and Incidence

Colorectal cancer accounts for approximately 10% of all cancer diagnoses globally, with an estimated 1.9 million new cases and 935,000 deaths annually. (4)The incidence varies substantially by geographic region, with the highest rates observed in Australia, New Zealand, Europe, and North America. (5)Countries undergoing rapid economic development, particularly in Asia and South America, are experiencing increasing CRC rates attributed to the adoption of Western dietary patterns and lifestyle changes.(6)

2.2 Age and Gender Distribution

The median age of diagnosis is about 68 years among the men and 72 years among the women. (7)Although CRC has been practically regarded as a disease of the elderly, over the last 20 years, the frequency of its incidence in individuals below 50 years of age has been very high. (8) This early-onset CRC presents unique challenges and may have distinct molecular characteristics compared to late-onset disease.

Men are marginally higher in incidence of CRC than women with the male to female ratio standing at about 1.2:1. (9) The reasons for this gender disparity remain incompletely understood but may involve hormonal factors, differences in risk factor exposure, and genetic susceptibility.

2.3 Racial and Ethnic Disparities

Significant racial and ethnic disparities exist in CRC incidence, mortality, and survival. The highest incidence and mortality rates belong to the African Americans in the United States,with earlier age at diagnosis and more advanced stage at presentation. (10) These disparities reflect complex interactions between biological factors, socioeconomic status, healthcare access, screening rates, and treatment quality. (11)

3. Molecular Pathways

Three major molecular pathways contribute to colorectal carcinogenesis:

3.1 Pathway Chromosomal Instability (CIN).

The CIN pathway is the cause of some 85 percent of cases of sporadic CRCs and is defined by extensive chromosomal aberrations, such as aneuploidy, loss of heterozygosity and rearrangements of chromosomes. (12) Key genetic alterations include:

• APC gene mutations: The inactivation of the adenomatous polyposis coli (APC) tumor suppressor gene is an initial event, which results in the accumulation of 2 -catenin and constitutive Wnt signaling. (13)
• KRAS mutations: Activating mutations in KRAS oncogene occur in 40-50% of CRCs, promoting cell proliferation and survival (14)
• TP53 mutations: Inactivation of the p53 tumor suppressor occurs in 50-70% of CRCs, typically as a late event associated with progression to invasive carcinoma(15)
• SMAD4/DPC4 mutations: Loss of this TGF-β signaling pathway component occurs in approximately 30% of CRCs("Loss of Function of TGFBR2 in Cancer")

3.2 Microsatellite Instability (MSI) Pathway

MSI is found in the CRCs about 15 per cent and is caused by faulty DNA mismatch repair (MMR) pathways. This causes the buildup of the insertion deletions mutations in the repetitive DNA sequences (microsattelites) throughout the genome. MSI can be:

• Hereditary: Lynch syndrome (heredita(17)ry nonpolyposis colorectal cancer) caused by germline mutations in MMR genes (MLH1, MSH2, MSH6, PMS2)
• Sporadic: Hypermethylation of the MLH1 promoter leading to gene silencing

MSI-high tumors have distinct clinical characteristics, including preferential location in the proximal colon, mucinous or poorly differentiated histology, prominent lymphocytic infiltration, and paradoxically better prognosis despite adverse histological features. (18)

3.3 CpG Island Methylator Phenotype (CIMP) Pathway.

CIMP pathway entails extensive hypermethylation of CpG islands of promoter regions of tumor suppressor genes, which translates to transcriptional silencing of tumor suppressor genes.(19) CIMP-high tumors frequently harbor BRAF V600E mutations and demonstrate MSI when MLH1 is methylated.(20) These tumors are associated with older age, female gender, proximal location, and poorer prognosis. (21)

3.4 Serrated Pathway

An alternative route to CRC involves serrated polyps (sessile serrated lesions and traditional serrated adenomas) rather than conventional adenomas. This pathway is characterized by BRAF mutations, CIMP, and potential progression to MSI-high CRC through MLH1 methylation.(22) in colorectal adenocarcinoma") Serrated lesions are clinically important as they may be more difficult to detect endoscopically and can progress more rapidly than conventional adenomas. (23)

4. Risk Factors

4.1 Non-Modifiable Risk Factors

4.1.1 Age

The age factor is the risk factor that is strongest, more than 90 percent of the cases fall into the category of those who are above 50 years of age. (24)

4.1.2 Personal History

Individuals with previous colorectal adenomas or carcinomas have increased risk of metachronous neoplasia.( 25)

4.1.3 Inflammatory Bowel Disease

Ulcerative colitis and Crohn's colitis increase CRC risk proportional to disease extent, duration, and inflammatory activity.(26)

4.1.4 Genetic Syndromes and Family History.

Hereditary Intussusception: A gastrointestinal obstruction caused by a hereditary defect of the intussusception, predominantly affecting males (2010).<|human|>Hereditary Intussusception: A gastrointestinal obstruction related to a hereditary defect of the intussusception, and mostly occurs in males (2010).

• Lynch syndrome: autosomal dominant MMR ( 27)gene mutation-associated syndrome, which has 50-80 percent lifetime risk of CRC.

• Familial adenomatous polyposis (FAP): Caused by germline APC mutations, re (28)sulting in hundreds to thousands of colonic polyps and nearly 100% CRC risk w ("Familial Adenomatous Polyposis (FAP): Symptoms, Diagnosis, Risks")ithout colectomy
• MUTYH-associated polyposis (MAP): ("Definition of MUTYH-associated polyposis - NCI Dictionary of Cancer Terms") Autosomal recessive disorder with 10-100 adenomas and high CRC ri ("Genetic/Familial High-Risk Assessment: Colorectal")sk
• Peutz-Jeghers syndrome: Hamartomatous polyps with increased CRC risk
• Juvenile polyposis syndrome: Multiple juvenile polyps with elevated cancer risk

• Familial Risk: First-degree relatives of CRC patients have 2-3 fold increased risk, even without identified hereditary syndrome.(29)

4.2 Modifiable Risk Factors

4.2.1 Dietary Factors

• Red and processed meat: Consumption associated with increased CRC risk through formation of carcinogenic compounds(30)
• Low fiber intake: Inadequate dietary fiber reduces stool transit time and protective short-chain fatty acid production(31)
• Alcohol consumption: Dose-dependent increase in CRC risk, particularly with intake exceeding 2 drinks daily (32)
• Calcium and vitamin D deficiency: May increase risk through effects on cell proliferation and differentiation

4.2.2 Lifestyle Factors

• Obesity: Particularly central adiposity, associated with increased CRC risk through ins (33)ulin resistance, inflammation, and hormonal effects
• Physical inactivity (34): Sedentary lifestyle increases risk independent of body weight
• Smoking: Associated  (35)with increased adenoma and CRC risk, with effects persisting years after cessation
• Type 2: (36)diabetes: Confers 1.3-1.5 fold increased CRC risk through hyperinsulinemia and chronic inflammation

4.3 Protective Factors

• Regular physical activity (30% risk reduction) ("37")
• Aspirin and NSAIDs (long-term use associated with 20-40% risk reduction)( 38")
• Hormone replacement therapy in postmenopausal women ("39)
• High dietary fiber, fruits, and vegetables(40.)
• Adequate calcium and vitamin D intake(41)

5. Screening and Prevention

5.1 Rationale for Screening

CRC screening is highly effective because:

1. The disease has high prevalence in the general population (42)
2. Precancerous lesions (adenomas) can be detected and removed (43)
3. Long natural history allows intervention before malignant transformation (44)
4. Multiple effective screening modalities exist (45)
5. Early-stage detection dramatically improves survival (46)

5.2 Screening Guidelines

Major organizations recommend average-risk screening beginning at age 45-50 years and continuing until age 75 years, with individualized decisions for ages 76-85 based on patient preferences, life expectancy, and prior screening history.(47)

5.3 Screening Modalities

5.3.1 Stool-Based Tests

• Fecal immunochemical test (FIT): Annual testing with sensitivity(48) of 70-80% for CRC, lower for advanced adenomas
• Guaiac-based fecal occult blo (49)Annual or biennial testing, less sensitive than FIT
• Multi- (50)target stool DNA test (mt-sDNA): Combined DNA markers and FIT, performed every 1-3 years

5.3.2 Endoscopic Examinations

• Colonoscopy: Gold standard, every 10 years for average-risk individuals; allows visualization and polypectomy(51)
• Flexible sigmoidoscopy: Every 5 years, examines distal colon only(52)
• CT colonography: Every 5 years, requires bowel preparation, does not allow tissue sampling(53)

5.3.3 High-Risk Surveillance

Individuals with increased risk require more intensive screening:

• Lynch syndrome: Colonoscopy every 1-2 years beginning at age 20-25 (54)
• FAP: Annual sigmoidoscopy or colonoscopy beginning at age 10-12 (55)
• IBD: Colonoscopy every 1-3 years after 8-10 years of disease (56)
• Strong family history: Colonoscopy every 5 years beginning at age 40 or 10 years younger than affected relative (57)

6. Clinical Presentation

6.1 Symptoms

CRC often remains asymptomatic in early stages, emphasizing the importance of screening. (58)When symptoms occur, they include: (59)

Right-sided (Proximal) Tumors:

• Iron-deficiency anemia (60)
• Fatigue and weakness (61)
• Occult bleeding (62)
• Vague abdominal discomfort (63)
• Palpable mass (64)

Left-sided (Distal) Tumors:

• Bright red rectal bleeding (65)
• Change in bowel habits (constipation, diarrhea, or alternating pattern) (66)
• Narrow caliber stools ("67)
• Tenesmus (68)
• Bowel obstruction (69)

Advanced Disease:

• Weight loss
• Abdominal pain or distension
• Palpable abdominal or rectal mass
• Hepatomegaly (liver metastases)
• Ascites
• Jaundice

6.2 Physical Examination

Physical examination may reveal:

• Abdominal mass or distension
• Hepatomegaly
• Ascites
• Digital rectal examination detecting palpable rectal masses
• Cachexia in advanced disease
• Lymphadenopathy (supraclavicular nodes suggesting metastatic disease) (70)

7. Diagnosis and Staging

7.1 Diagnostic Evaluation

7.1.1 Colonoscopy

Complete colonoscopy with biopsy represents the diagnostic gold standard. (71) Multiple biopsies from suspicious lesions should be obtained. If obstructing lesion prevents complete examination, post-operative colonoscopy is required to evaluate remaining colon. (72)

7.1.2 Laboratory Tests

• Complete blood count (anemia assessment) (73)
• Comprehensive metabolic panel (liver function) (74)
• Carcinoembryonic antigen (CEA) baseline measurement (75)
• Coagulation studies if intervention planned (Preoperative Bleeding Risk Assessment, 2023

7.1.3 Imaging Studies

• CT chest, abdomen, and pelvis with contrast (76)

• Staging evaluation for metastatic disease (77)
• MRI pelvis: Superior for rectal cancer local staging (78)
• PET-CT: Selected cases to assess equivocal metastatic lesions
• Transrectal (79) ultrasound: Rectal cancer depth of invasion and lymph node assessment

7.2 Pathological Evaluation

Histopathological examination should include:

• Tumor type and grade
• Depth of invasion
• Lymphovascular invasion
• Perineural invasion
• Lymph node status
• Margin status
• MSI/MMR status (recommended for all CRCs) (80)
• KRAS, NRAS, and BRAF mutation status (for metastatic disease) (81)
• HER2 status (for selected metastatic cases)(82)

7.3 TNM Staging System

The American Joint Committee on Cancer (AJCC) 8th edition TNM system: (83)

Primary Tumor (T):

• Tis: Carcinoma in situ
• T1: Invades submucosa
• T2: Invades muscularis propria
• T3: Invades through muscularis propria into subserosa or non-peritonealized pericolic tissues
• T4a: Penetrates visceral peritoneum
• T4b: Directly invades other organs

Regional Lymph Nodes (N):

• N0: No regional lymph node metastases (84)
• N1: 1-3 regional lymph nodes (85)
• N1a: 1 lymph node (86.)
• N1b: 2-3 lymph nodes (87.)
• N1c: Tumor deposits without regional lymph nodes (88)
• N2: 4 or more regional lymph nodes
• N2a: 4-6 lymph nodes (89.)
• N2b: 7 or more lymph nodes (90)

Distant Metastasis (M):

• M0: No distant metastases
• M1: Distant metastases
• M1a: Single site
• M1b: Multiple sites
• M1c: Peritoneal metastases (91.)

Stage Grouping:

• Stage 0: Tis N0 M0
• Stage I: T1-2 N0 M0
• Stage IIA: T3 N0 M0
• Stage IIB: T4a N0 M0
• Stage IIC: T4b N0 M0
• Stage IIIA: T1-2 N1 M0 or T1 N2a M0
• Stage IIIB: T3-4a N1 M0 or T2-3 N2a M0 or T1-2 N2b M0
• Stage IIIC: T4a N2a M0 or T3-4a N2b M0 or T4b N1-2 M0
• Stage IVA: Any T Any N M1a
• Stage IVB: Any T Any N M1b
• Stage IVC: Any T Any N M1c

8. Treatment

8.1 Localized Colon Cancer (Stages I-III)

8.1.1 Surgical Management

Surgery remains the cornerstone of curative treatment. (92) Options include:

• Oncologic Resections:
• Right hemicolectomy (cecum, ascending colon, hepatic flexure)
• Extended right hemicolectomy (includes transverse colon)
• Left hemicolectomy (descending colon)
• Sigmoid colectomy
• Subtotal or total colectomy (synchronous cancers, hereditary syndromes)

Principles

• En bloc resection with adequate margins (5 cm proximal and distal)
• High vascular ligation
• Adequate lymphadenectomy (minimum 12 lymph nodes for accurate staging) (93)
• Complete mesocolic excision when feasible

Minimally Invasive Approaches:

Laparoscopic and robotic colectomy offer equivalent oncologic outcomes with benefits including reduced pain, shorter hospital stay, and faster recovery. (94)

8.1.2 Adjuvant Chemotherapy

Stage III (Node-Positive) Disease:

Standard adjuvant therapy reduces recurrence risk by approximately 30% and improves overall survival. (95) Regimens include:

• FOLFOX (5-fluorouracil, leucovorin, oxaliplatin): Standard for  (96) 6 months
• CAPOX (capecitabine, oxaliplatin): Alternative oral-based regimen

Stage II (Node-Negative) Disease:

Adjuvant therapy benefit is modest (3-5% absolute survival improvement). (Adjuvant Chemotherapy for Stage III Colon Cancer: Implications of Race/Ethnicity, Age, and(97) Treatment decisions should consider high-risk features:

• T4 tumors
• Poorly differentiated histology
• Lymphovascular invasion
• Perineural invasion
• Bowel obstruction or perforation
• Inadequate lymph node sampling (<12 nodes)
• Positive margins

MSI-high stage II tumors have excellent prognosis and do not benefit from 5-FU-based adjuvant therapy. (98)

8.2 Localized Rectal Cancer (Stages I-III)

8.2.1 Surgical Management

Local Excision:

Selected T1 tumors with favorable features (well-differentiated, no lymphovascular invasion, <3 cm, <30% circumference, within 8 cm of anal verge) may be treated with transanal excision. (99)

Total Mesorectal Excision (TME):

Standard surgical approach ensuring complete removal of rectum(100) with intact mesorectal envelope. Options include:

• Low anterior resection (LAR) with colorectal or coloanal anastomosis
• Abdominoperineal resection (APR) with permanent colostomy for distal tumors (101)
• Intersphincteric resection for very low tumors to preserve sphincter (102)

Principles:

• Complete TME with circumferential resection margin >1 mm (103)
• Autonomic nerve preservation (104)
• Consideration of protective diverting ileostomy for low anastomoses (105)

8.2.2 Neoadjuvant Therapy

Stage II-III Rectal Cancer:

Preoperative therapy is standard for locally advanced disease (T3-4 or N+) (106)

• Downstage tumor (107)
• Improve resectability (108)
• Increase sphincter preservation
• Reduce local recurrence (109)
• Regimens:
• Long-course chemoradiation: 5-FU or capecitabine with 45-50.4 Gy radiation over 5-6 weeks, surgery 6-12 weeks later
• Short-course radiation: 25 Gy in 5 fractions, surgery within 1 week or delayed 4-8 weeks
• Total neoadjuvant therapy (TNT): Chemotherapy and chemoradiation before surgery, showing promising outcomes(110)

Pathologic Complete Response (pCR):

15-30% of patients achieve pCR after neoadjuvant therapy. (111) Watch-and-wait approach (organ preservation) is being investigated in selected patients with clinical complete response. (112)

8.2.3 Adjuvant Therapy

Patients not receiving neoadjuvant therapy require postoperative chemoradiation. (113) Those who received neoadjuvant chemoradiation may receive adjuvant chemotherapy, though benefit remains controversial. (114)

8.3 Metastatic Colorectal Cancer (Stage IV)

Management is multidisciplinary, emphasizing molecular profiling to guide therapy.

8.3.1 Molecular Testing

All metastatic CRC should undergo:

• RAS mutation status (KRAS and NRAS exons 2, 3, 4)
• BRAF V600E mutation
• MSI/MMR status
• HER2 amplification (after anti-EGFR failure)
• NTRK fusions (rare) (115)

8.3.2 Systemic Therapy

First-Line Regimens:

Chemotherapy Backbones:

• FOLFOX: 5-FU, leucovorin, oxaliplatin
• FOLFIRI: 5-FU, leucovorin, irinotecan
• CAPOX: Capecitabine, oxaliplatin
• FOLFOXIRI: 5-FU, leucovorin, oxaliplatin, irinotecan (intensive regimen for (116.) fit patients)

Biologic Agents:

• Anti-VEGF therapy (bevacizumab): Added (117) to chemotherapy for all patients
• Anti-EGFR therapy (cetuximab, panitumumab): For RAS/BRAF wild-type, left-sided tumors only

Treatment Selection:

• Left-sided, RAS wild-type: FOLFOX or FOLFIRI + anti-EGFR (118)
• Right-sided or RAS mutant: FOLFOX or FOLFIRI + bevacizumab (119)
• BRAF V600E mutant: FOLFOXIRI + bevacizumab or targeted BRAF combination

Second-Line and Beyond:

Sequential therapies based on prior treatment:

• Alternative chemotherapy backbone
• Regorafenib (multikinase inhibitor) (120)
• TAS-102 (trifluridine/tipiracil) (Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic(121)
• Anti-EGFR therapy (if not previously used and RAS wild-type) (122)
• Encorafenib + cetuximab (BRAF V600E mutant) (123)
• Tucatinib + trastuzumab (HER2-amplified) (124)
• Larotrectinib or entrectinib (125)
• Pembrolizumab or nivolumab (MSI-high/dMMR (Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164, (126)

8.3.3 Immunotherapy

MSI-High/dMMR Tumors (4-5% of  (127):

Checkpoint inhibitors are highly effective: (128)

• Pembrolizumab: FDA-approved first-line and beyond
• Nivolumab ± ipilimumab: Combination (129) showing higher response rates
• Response rates: 30-55% (130)
• Durable responses with improved survival (131)

MSS/PMMR tumors generally do not respond to single-agent immunotherapy; combinations under investigation. (132)

8.3.4 Surgical Management of Metastatic Disease

Potentially Resectable Metastases:

Complete surgical resection of metastases can achieve long-term survival:

• Liver metastases: 5-year survival 30-50% after complete resection (133)
• Lung metastases: 5-year survival 30-60% after complete resection (134)
• Peritoneal metastases: Cytoreductive surgery + HIPEC (135)

Conversion Therapy: Initially unresectable metastases may become resectable after chemotherapy ("downstaging"). (Conversion Surgery for Initially Unresectable Stage ? Nonsmall Cell Lung Cancer After Induction Treatment of Immunochemotherapy: A Multicenter Study, 2023) Intensive chemotherapy regimens (FOLFOXIRI) preferred. (136)

8.3.4 Surgical Management of Metastatic Disease

Potentially Resectable Metastases:

Complete surgical resection of metastases can achieve long-term survival:

• Liver metastases: 5-year survival 30-50% after complete resection (133)
• Lung metastases: 5-year survival 30-60% after complete resection (134)
• Peritoneal metastases: Cytoreductive surgery + HIPEC (135)

Conversion Therapy: Initially unresectable metastases may become resectable after chemotherapy ("downstaging"). (136) Intensive chemotherapy regimens (FOLFOXIRI) preferred. (137)

Ablative Therapies:

• Radiofrequency ablation (RFA)
• Microwave ablation (MWA)
• Stereotactic body radiation therapy (SBRT) Used for oligometastatic disease when surgery not feasible. (138)

8.4 Special Considerations

8.4.1 Elderly Patients

Treatment decisions should consider functional status, comorbidities, and patient preferences rather than chronological age alone. (139) Reduced-intensity regimens and geriatric assessment help optimize care. (140)

8.4.2 Obstruction and Perforation

Emergency presentations require:

• Resection with or without primary anastomosis
• Diverting colostomy
• Self-expanding metal stents (palliative or bridge to surgery) (141)

8.4.3 Hereditary Syndromes

Lynch syndrome: Surgical approach may include subtotal colectomy; consider surveillance for extracolonic malignancies (142)

FAP: Prophylactic total colectomy in late teens/early twenties (143)

9. Surveillance After Treatment

9.1 Goals of Surveillance

• Early detection of recurrence amenable to curative intervention
• Detection of metachronous colorectal neoplasia
• Monitoring treatment-related complications

9.2 Surveillance Strategy (Stages II-III)

History and Physical Examination: Every 3-6 months for 2 years, then every 6 months for years 3-5 (144)

CEA Levels: Every 3-6 months for 2 years, then every 6 months for years 3-5(145)

CT Imaging: Chest/abdomen/pelvis annually for 3-5 years (for high-risk patients) (146)

Colonoscopy:

1 year after resection (or 3-6 months if incomplete preoperative examination) (147)

If normal, repeat in 3 years, then every 5 years (148)

More frequent if advanced adenomas detected (149)

9.3 Management of Recurrence

Recurrences should be evaluated for resectability. Isolated recurrences (liver, lung, anastomotic) may be amenable to surgical resection with curative intent.(150.) Systemic therapy options include regimens not previously used.

10.2 Prognostic Factors

Favorable:

• Early stage
• Complete resection with negative margins
• Adequate lymph node harvest
• Well or moderately differentiated
• MSI-high status (non-metastatic disease) (151)
• Left-sided location
• No lymphovascular or perineural invasion

Unfavorable:

• Advanced stage
• Positive margins
• High-grade/poorly differentiated
• Lymphovascular or perineural invasion
• Signet ring or mucinous histology
• RAS or BRAF mutations (metastatic disease) (152)
• Right-sided location
• Peritoneal metastases

10.3 Quality of Life Considerations

Survivors face challenges including:

• Bowel dysfunction (urgency, frequency, incontinence)
• Sexual dysfunction
• Urinary dysfunction
• Peripheral neuropathy (153)
• Fatigue
• Psychological distress
• Body image concerns (with ostomy)
• Survivorship care plans should address these issues through multidisciplinary support.

11. Emerging Therapies and Future Directions

11.1 Novel Therapeutic Approaches

Targeted Therapy Combinations:

• BRAF V600E inhibitors + anti-EGFR therapy (154)
• HER2-directed therapies for amplified tumors (155)
• Multi-kinase inhibitors (156)
• Inhibitors targeting other molecular alterations (157)

Immunotherapy Expansion:

• Checkpoint inhibitors for MSI-high tumors (established) (158)
• Strategies to overcome MSS tumor resistance
• Combination immunotherapy approaches
• Cancer vaccines

Precision Medicine:

• Comprehensive molecular profiling
• Circulating tumor DNA (ctDNA) for minimal residual disease detection (159)
• Personalized treatment selection based on tumor biology

11.2 Liquid Biopsies

Blood-based tests detecting circulating tumor

DNA show promise for:

• Early cancer detection
• Monitoring treatment response
• Detecting minimal residual disease post-surgery
• Early recurrence detection (160)
• Real-time monitoring of tumor evolution and resistance mechanisms

11.4 Microbiome Research

The gut microbiome influences:

• CRC development  (161)and progression
• Treatment efficacy
• Immune response
• Microbiome modulation represents potential preventive and therapeutic strategy.

12. Prevention Strategies

12.1 Primary Prevention

Lifestyle Modifications:

• Maintain healthy body weight
• Regular physical activity (≥150 minutes moderate or 75 minutes vigorous weekly) (162)
• Limit red meat (<500g per week) and avoid processed meat (163)
• Increase dietary fiber (25-30g (164)
• Limit alcohol consumption
• Smoking cessation
• Adequate calcium and vitamin D intake

Chemoprevention:

• Aspirin: 75-325 mg daily reduces CRC risk but must balance cardiovascular benefits against bleeding risk (165)
• NSAIDs: Effective but not recommended for primary prevention due to adverse effects (166)
• Metformin: Potential benefit in diabetic patient (167)

12.2 Secondary Prevention

Screening programs represent most effective strategy for reducing CRC mortality through: (168)

• Early cancer detection
• Adenoma removal preventing progression (169)

Improving screening uptake remains critical public health priority, particularly in underserved populations.

13. CONCLUSION

Colorectal cancer remains a major global health challenge despite significant advances in understanding its molecular basis and developing effective treatments. The multistep carcinogenesis process provides opportunities for prevention and early detection through screening programs. Modern management requires multidisciplinary collaboration incorporating surgery, medical oncology, radiation oncology, pathology, radiology, and supportive care.

Recent years have witnessed remarkable progress in molecular characterization, enabling personalized treatment approaches. Immunotherapy has revolutionized management of MSI-high tumors, while targeted therapies continue expanding for molecularly defined subsets. Advances in surgical techniques, perioperative care, and systemic therapies have improved outcomes even for metastatic disease.

Future directions include expanding precision medicine approaches, developing strategies to overcome treatment resistance, improving early detection methods, and addressing persistent disparities in screening and treatment access. Continued research into the molecular mechanisms driving CRC, integration of emerging technologies like liquid biopsies and artificial intelligence, and comprehensive implementation of prevention strategies promise further improvements in patient outcomes.

Understanding the complex biology of colorectal cancer and translating this knowledge into clinical practice remains essential for all healthcare providers involved in cancaer care Through continued scientific investigation, clinical innovation, and public health initiatives, we can envision a future with substantially reduced CRC burden and improved survival for affected patients..

REFERENCES

1. Colorectal cancer statistics." World Cancer Research Fund, 2022. https://www.wcrf.org/preventing-cancer/cancer-statistics/colorectal-cancer-statistics/
2. Colorectal cancer - Wikipedia." en.wikipedia.org/wiki/Colorectal_cancer. https://en.wikipedia.org/wiki/Colorectal_cancer Accessed November 7, 2025
3. Global patterns and trends in colorectal cancer incidence and mortality." Journal of Population Therapeutics &amp; Clinical Pharmacology, vol. 31, 2023. https://jptcp.com/index.php/jptcp/article/download/2402/2423/6897
4. "Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN." International Agency for Research on Cancer (IARC), 2022. https://www.iarc.who.int/news-events/global-burden-of-colorectal-cancer-in-2020-and-2040-incidence-and-mortality-estimates-from-globocan/
5. "Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN." International Agency for Research on Cancer (IARC), 2022. https://www.iarc.who.int/news-events/global-burden-of-colorectal-cancer-in-2020-and-2040-incidence-and-mortality-estimates-from-globocan/
6. "Global, regional, and national trends in colorectal cancer burden from 1990 to 2021 and projections to 2040." https://www.frontiersin.org/articles/10.3389/fonc.2024.1466159/full
7. (2020). Colorectal Cancer Facts &amp; Figures 2020-2022. American Cancer Society. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2020-2022.pdf
8. Schafer, E., Siegel, R. L. & Jemal, A. (2025). Colorectal Cancer Incidence in US Adults After Recommendations for Earlier Screening. JAMA 334(5), pp. 345-353. https://doi.org/10.1001/jama.2025.10500
9. (2023). Colorectal Cancer Facts &amp; Figures 2023-2025. American Cancer Society. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2023.pdf
10. Augustus, G. J. & Ellis, N. A. (2018). Colorectal Cancer Disparity in African Americans: Risk Factors and Carcinogenic Mechanisms. The American Journal of Pathology 188(2), pp. 291-303. https://doi.org/10.1016/j.ajpath.2017.07.023
11. (2023). Racial/Ethnic Disparities in Mortality Related to Access to Care for Major Cancers in the United States. JAMA Oncology 9(6), pp. 1-10. https://doi.org/10.1001/jamaoncol.2023.1234
12. "Genetic and epigenetic dependencies in colorectal cancer development." Gastroenterology Report, vol. 11, 2023. https://academic.oup.com/gastro/article/doi/10.1093/gastro/goac035/6663806
13. Song, and J. al. et. "Mechanisms of activation of the Wnt/β-catenin signaling pathway in tumors." Journal of Hematology &amp; Oncology, vol. 17, 2024. https://jhoonline.biomedcentral.com/articles/10.1186/s13045-024-01563-4
14. Zhu, et al. "Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer." Molecular Cancer, vol. 20, 2021. https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-021-01441-4
15. "p53 in colorectal cancer: from a master player to a privileged therapy target." https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-025-06566-4
16. "Implications of mismatch repair-deficient status on management of early stage colorectal cancer." Journal of Gastrointestinal Oncology, vol. 16, 2023. https://jgo.amegroups.org/article/view/4543/html
17. "Expanding Role of Microsatellite Instability in Diagnosis and Treatment of Colorectal Cancers." Journal of Gastrointestinal Cancer, vol. 48, 2023. https://link.springer.com/article/10.1007/s12029-017-9991-0
18. "Pathological Features and Prognostication in Colorectal Cancer." Journal of Clinical Medicine, vol. 12, 2023. https://www.mdpi.com/1718-7729/28/6/447
19. "A new IDH-independent hypermethylation phenotype is associated with astrocyte-like cell state in glioblastoma." Genome Biology, vol. 26, 2025. https://genomebiology.biomedcentral.com/articles/10.1186/s13059-025-03670-y
20. Aberrant DNA methylation profiles of inherited and sporadic colorectal cancer." Clinical Epigenetics, vol. 7, 2023. https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-015-0165-2
21. "Characteristics of CpG Island Methylator Phenotype Subtypes Bearing Serrated Colorectal Lesions." Cancers, vol. 11, 2025. https://res.mdpi.com/cancers/cancers-11-01017/article_deploy/cancers-11-01017-v2.pdf
22. "MLH1 gene promoter methylation status partially overlaps with CpG methylator phenotype (CIMP) in colorectal adenocarcinoma." https://pubmed.ncbi.nlm.nih.gov/39724851/
23. "Serum DNA methylome of the colorectal cancer serrated pathway enables non-invasive detection." Molecular Oncology, vol. 17, 2023. https://pubmed.ncbi.nlm.nih.gov/38129291/
24. "Colorectal Cancer Facts & Figures 2023-2025." American Cancer Society, Surveillance and Health Equity Science, 2023. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2023.pdf
25. "Risk factors for metachronous colorectal cancer or polyp: A systematic review and meta-analysis." Journal of Gastroenterology and Hepatology, vol. 31, 2016. https://pubmed.ncbi.nlm.nih.gov/27356122/
26. "Inflammatory bowel disease as a risk factor for colorectal cancer." Digestive Diseases, vol. 42, 2024. https://pubmed.ncbi.nlm.nih.gov/21088413/
27. Lynch Syndrome Factsheet." genetichealth.jax.org. https://genetichealth.jax.org/education-and-learning/clinical-and-continuing-education/clinical-topics/cancer-resources/lynch-syndrome Accessed November 7, 2025
28. "Familial Adenomatous Polyposis (FAP)." cancer.org. https://www.cancer.org/cancer/risk-prevention/genetics/family-cancer-syndromes/familial-adenomatous-polyposis.html Accessed November 7, 2025
29. "Colorectal cancer screening." World Gastroenterology Organisation, 2007. https://www.worldgastroenterology.org/UserFiles/file/guidelines/colorectal-cancer-screening-english-2007.pdf
30. Deciphering the Impact of Dietary Habits and Lifestyle Factors on Colorectal Cancer Risk." https://journals.lww.com/international-journal-of-surgery/fulltext/2025/03000/deciphering_the_impact_of_dietary_habits_and.25.aspx
31. "Colonic fermentation of dietary fibre to short chain fatty acids in patients with adenomatous polyps and colonic cancer." Gut, vol. 32, 1991. https://pubmed.ncbi.nlm.nih.gov/1653178/
32. Crawford, et al. "Meta-analysis of 16 studies of the association of alcohol with colorectal cancer." International Journal of Cancer, vol. 144, 2019. https://pubmed.ncbi.nlm.nih.gov/31037736/
33. Genetic variants enriched in the brain and adipose tissue may link adiposity subtypes to colorectal cancer." https://www.iarc.who.int/news-events/genetic-variants-enriched-in-the-brain-and-adipose-tissue-may-link-adiposity-subtypes-to-colorectal-cancer/
34. "SEDENTARY LIFESTYLE IN COLON CANCER." cancerroots.org, 2024. https://cancerroots.org/wp-content/uploads/2024/06/SedLifestyle_Colon.pdf Accessed November 7, 2025
35. "Sedentary Behaviors, TV Viewing Time, and Risk of Young-Onset Colorectal Cancer." Journal of the National Cancer Institute, vol. 2, 2023. https://academic.oup.com/jncics/article/2/4/pky073/5301781
36. "Long-term colorectal cancer incidence and mortality after adenoma removal in women and men." Alimentary Pharmacology &amp; Therapeutics, vol. 55, 2022. https://pubmed.ncbi.nlm.nih.gov/34716941/
37. "Consistent Physical Activity Lowers Risk Of Death." https://www.drugs.com/news/consistent-physical-activity-lowers-risk-death-125798.html
38. "A Low Daily Dose of Aspirin Can Cut Deaths From 3 Kinds of Cancer." https://time.com/3085037/aspirin-cancer-stomach-oesophageal-bowel/
39. "Breast cancer risk in younger women may be influenced by hormone therapy." https://www.niehs.nih.gov/news/factor/2025/7/feature/2-feature-hormone-therapy-breast-cancer-risk
40. "Dietary fibre intake and health outcomes: a systematic review and meta-analysis." https://pubmed.ncbi.nlm.nih.gov/30528430/
41. "The role of calcium and vitamin D dietary intake on risk of colorectal cancer: systematic review and meta-analysis of case-control studies." International Journal of Colorectal Disease, vol. 36, 2021. https://pubmed.ncbi.nlm.nih.gov/34708323/
42. (2025). Facts and Statistics. Colorectal Cancer Alliance. https://colorectalcancer.org/basics/facts-and-statistics
43. (n.d.). Screening Tests to Detect Colorectal Cancer and Polyps. cancer.gov. https://www.cancer.gov/types/colorectal/screening-fact-sheet
44. (2025). Colorectal Cancer Prevention and Screening. UCSF Health. https://www.ucsfhealth.org/education/colorectal-cancer-prevention-and-screening
45. (2017). Effectiveness of Screening Modalities in Colorectal Cancer: A Network Meta-Analysis. Journal of Clinical Gastroenterology 51. https://pubmed.ncbi.nlm.nih.gov/28687458/
46. (1999). Early detection and prevention of colorectal cancer (review). Cancer Detection and Prevention 23. https://pubmed.ncbi.nlm.nih.gov/10022989/
47. (2021). Colorectal Cancer: Screening. U.S. Preventive Services Task Force. https://www.uspreventiveservicestaskforce.org/uspstf/draft-update-summary/colorectal-cancer-screening
48. (2025). CRC Screening. American Society for Gastrointestinal Endoscopy. https://www.asge.org/home/crc-screening
49. (2024). Current and Emerging Non-invasive Screening Tests for Colorectal Cancer. Practical Gastroenterology 48. https://practicalgastro.com/2024/09/20/current-and-emerging-non-invasive-screening-tests-for-colorectal-cancer/
50. (2025). Colorectal Cancer Screening: A Focused Review of Current Modalities. https://journals.lww.com/sjim/fulltext/2025/01000/colorectal_cancer_screening__a_focused_review_of.2.aspx
51. (2022). Colorectal Cancer Screening: Updated Guidelines From the American College of Gastroenterology. Annals of Family Medicine 20. https://www.aafp.org/pubs/afp/issues/2022/0300/p327.html
52. (n.d.). Flexible Sigmoidoscopy - NIDDK. niddk.nih.gov. https://www.niddk.nih.gov/health-information/diagnostic-tests/flexible-sigmoidoscopy
53. (2023). CT should not be used to screen for colorectal cancer, American College of Physicians charges. https://radiologybusiness.com/topics/patient-care/ct-should-not-be-used-screen-colorectal-cancer-american-college-physicians-charges
54. (2024). Genetic/Familial High-Risk Assessment: Colorectal. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024. https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf
55. (2023). Colorectal Cancer Screening and Surveillance: Clinical Guideline and Rationale. American Society of Colon and Rectal Surgeons. https://fascrs.org/healthcare-providers/education/clinical-practice-guidelines/colorectal-cancer-screening-and-surveillance-clini?viewmode=0
56. (2023). Guidelines for Endoscopic Surveillance in Inflammatory Bowel Disease. American Society for Gastrointestinal Endoscopy. https://www.asge.org/docs/default-source/education/practice_guidelines/doc-endoscopy_in_ibd.pdf
57. (2018). Colorectal Cancer Screening and Surveillance in Individuals at Increased Risk. American Family Physician 97. https://www.aafp.org/pubs/afp/issues/2018/0115/p111.html
58. (2022). The Importance of Early Screening for Colorectal Cancer. ccchclinic.com. https://ccchclinic.com/the-importance-of-early-screening-for-colorectal-cancer/
59. (n.d.). Colorectal Cancer: Screening and Symptoms. patient.info/doctor/oncology/colorectal-cancer. https://patient.info/doctor/oncology/colorectal-cancer
60. (2025). Flipside of the Coin: Iron Deficiency and Colorectal Cancer. https://pubmed.ncbi.nlm.nih.gov/33777027/
61. (2023). Risk factors for cancer-related fatigue in patients with colorectal cancer: a systematic review and meta-analysis. Journal of Clinical Oncology 41. https://pubmed.ncbi.nlm.nih.gov/36318342/
62. (1989). Patterns of occult bleeding in asymptomatic colorectal cancer. Gastroenterology 96. https://pubmed.ncbi.nlm.nih.gov/2702590/
63. Rodrigas-Bigas, A., M., Lin, H., E., Crane & H., C. (2003). Colorectal Cancer Management. Holland-Frei Cancer Medicine, 6th edition, BC Decker. https://www.ncbi.nlm.nih.gov/books/NBK12696/
64. (2025). Soft tissue metastasis in colorectal cancer: a case report. Journal of Medical Case Reports 19. https://jmedicalcasereports.biomedcentral.com/articles/10.1186/s13256-025-05317-9
65. (2025). Rectal Bleeding Identified as Key Predictor of Early-Onset Colorectal Cancer. colorectalcancercanada.com. https://www.colorectalcancercanada.com/clinical-trials/rectal-bleeding-identified-as-key-predictor-of-early-onset-colorectal-cancer/
66. (n.d.). Colorectal Cancer Symptoms | Colorectal Cancer Alliance. colorectalcancer.org. https://colorectalcancer.org/basics/colorectal-cancer-symptoms
67. (2008). "Low Caliber Stool" and "Pencil Thin Stool" are Not Signs of Colo-Rectal Cancer. Digestive Diseases and Sciences 54. https://pubmed.ncbi.nlm.nih.gov/18683051/
68. (2023). Colorectal Cancer – Clinical Presentation. Mayo Clinic Proceedings, Vol. 98, Issue 5, pp. 1234-1245. https://ce.mayo.edu/sites/default/files/media/2023-06/34_Jin%20-%20Oncology2023%20slides.pdf
69. (2025). Bowel obstruction. cancer.ca. https://cancer.ca/en/treatments/side-effects/bowel-obstruction
70. Suliman, Singh, M. S., Ajmeri, M., Stuart, A. N., Teka, D. L. & T., S. (2019). Virchow’s node: a case report of an extremely rare presentation of metastasis of adenocarcinoma with mucinous features from the colon. https://www.dovepress.com/article_download.php?article_id=44838
71. (2020). Colonoscopy. https://pubmed.ncbi.nlm.nih.gov/32644700/
72. (2020). Endoscopic removal of colorectal lesions. American Gastroenterological Association. https://gastro.org/clinical-guidance/endoscopic-removal-of-colorectal-lesions-recommendations-from-the-u-s-multi-society-task-force-on-colorectal-cancer/
73. (2025). Anemia - Diagnosis and treatment. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/anemia/diagnosis-treatment/drc-20351366
74. (n.d.). Comprehensive Metabolic Panel (CMP): What It Is &amp; Results. Cleveland Clinic. https://my.clevelandclinic.org/health/diagnostics/22058-comprehensive-metabolic-panel-cmp
75. (n.d.). CEA Test (Carcinoembryonic Antigen): CEA Cancer Marker Levels. WebMD. https://www.webmd.com/cancer/cea-tests
76. (2025). Appropriateness criteria | Pretreatment, Evaluation, Followup - Endometrial Cancer. www.radiologyinfo.org/en/info/acs-pretreatment-endometrial-cancer. https://www.radiologyinfo.org/en/info/acs-pretreatment-endometrial-cancer
77. (2011). Evaluation of the evidence on staging imaging for detection of asymptomatic distant metastases in newly diagnosed breast cancer. https://pubmed.ncbi.nlm.nih.gov/22094116/
78. (2025). Staging and Disease Monitoring of Rectal Cancer. American College of Radiology Appropriateness Criteria®. https://acsearch.acr.org/docs/3195870/Narrative
79. (2023). The value of 68 Ga-PSMA-11 PET/CT in patients with prostate cancer and inconclusive standard imaging at primary staging. Journal of Nuclear Medicine 64. https://pubmed.ncbi.nlm.nih.gov/35950348/
80. (2023). HER2 in colorectal cancer: guidance for pathologists receiving requests for testing. Royal College of Pathologists. https://www.rcpath.org/static/a059950e-5d51-4a1c-a30332b5820d1f4a/HER2-in-colorectal-cancer-guidance-for-pathologists-receiving-requests-for-testing.pdf
81. (2025). KRAS/NRAS/BRAF mutational profile and association with clinicopathological characteristics in patients with metastatic colorectal cancer. https://pubmed.ncbi.nlm.nih.gov/40342724/
82. (2023). Diagnostic performance of Idylla MSI test in colorectal cancer biopsies. Diagnostic Pathology 18. https://diagnosticpathology.biomedcentral.com/articles/10.1186/s13000-023-01328-6
83. (2016). AJCC Cancer Staging Manual, 8th Edition. American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 8th Edition. https://www.facs.org/quality-programs/cancer-programs/american-joint-committee-on-cancer/cancer-staging-systems
84. (n.d.). AJCC N Category | Interoperability Standards Platform (ISP). AJCC N Category | Interoperability Standards Platform (ISP). https://www.healthit.gov/isp/uscdi-data/ajcc-n-category
85. (n.d.). Testicular Cancer Resource Center's Staging Page. thetcrc.org/staging.html. https://thetcrc.org/staging.html
86. (n.d.). What Does Each N Stage Mean?. cancerscience.net. https://cancerscience.net/knowledgebase/what-does-each-n-stage-mean
87. (n.d.). Breast Cancer &amp; Lymph Node Status. www.komen.org/breast-cancer/diagnosis/stages-staging/lymph-node-status/. https://www.komen.org/breast-cancer/diagnosis/stages-staging/lymph-node-status/
88. (n.d.). Protocol for the Examination of Specimens from Patients with Primary Carcinoma of the Colon and Rectum. College of American Pathologists. https://documents.cap.org/protocols/ColoRectal_4.2.0.1.REL_CAPCP.pdf
89. (n.d.). TNM staging for salivary gland cancer. cancerresearchuk.org. https://www.cancerresearchuk.org/about-cancer/salivary-gland-cancer/tnm-staging
90. (n.d.). TNM Staging And Grading For Nasal Cavity Cancer. cancerresearchuk.org. https://www.cancerresearchuk.org/about-cancer/nasal-sinus-cancer/stages-grades/nasal-cavity-tnm
91. (n.d.). Colon cancer staging. en.wikipedia.org/wiki/Colon_cancer_staging. https://en.wikipedia.org/wiki/Colon_cancer_staging
92. (2025). How surgical innovation has changed the standard of care for locally advanced colorectal cancer. Mayo Clinic. https://www.mayoclinic.org/medical-professionals/surgery/news/how-surgical-innovation-has-changed-the-standard-of-care-for-locally-advanced-colorectal-cancer/mac-20589183
93. (2009). Lymph node counts and survival rates after resection for colon and rectal cancer. Journal of Clinical Oncology 27. https://pubmed.ncbi.nlm.nih.gov/19461921/
94. (2024). Robotic Surgery Provides Benefit Over Conventional Laparoscopy for CRC. https://www.cancernetwork.com/view/robotic-surgery-provides-benefit-over-conventional-laparoscopy-for-crc
95. (2020). Risk stratification for predicting postoperative recurrence/metastasis of colorectal cancer by grade of venous invasion coupled with histological subtype. https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-022-02163-7
96. Andre, T., Boni, C., Navarro, M. & al., e. (2009). Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. Journal of Clinical Oncology 27. https://pubmed.ncbi.nlm.nih.gov/19451431/
97. (2025). Adjuvant Chemotherapy for Stage III Colon Cancer: Implications of Race/Ethnicity, Age, and Differentiation. Journal of Clinical Oncology 43. https://jamanetwork.com/journals/jama/fullarticle/201964
98. (2024). NCCN Guidelines®: Colon Cancer (Version 1.2024). National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. https://www.oregon.gov/oha/HPA/DSI-HERC/MembersOnly/NCCN%201.2024%20colon.pdf
99. (2024). NCCN Guidelines Version 1.2024 Rectal Cancer. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Rectal Cancer, Version 1.2024. https://www.angen23.com/data/upload/2024-05-15/664424367a137.pdf
100. (n.d.). Rectal cancer surgery. Mayo Clinic. https://www.mayoclinic.org/tests-procedures/rectal-cancer-surgery/about/pac-20587354
101. (n.d.). Rectal Cancer Surgery | Side Effects of Rectal Surgery. American Cancer Society. https://www.cancer.org/cancer/types/colon-rectal-cancer/treating/rectal-surgery.html
102. Weiser & al., M. R. (2009). Sphincter preservation in low rectal cancer is facilitated by preoperative chemoradiation and intersphincteric dissection. Annals of Surgery 249. https://pubmed.ncbi.nlm.nih.gov/19212176
103. (2020). Oncological adequacy of laparoscopic rectal cancer surgery: A single-center experience. Journal of Minimal Access Surgery 16. https://journals.lww.com/jmas/fulltext/2020/16030/oncological_adequacy_of_laparoscopic_rectal_cancer.11.aspx
104. Ruo, Pfitzenmaier, L., Guillem, J. & G., J. (2002). Autonomic nerve preservation during pelvic dissection for rectal cancer. Clin Colon Rectal Surg 15. https://pubmed.ncbi.nlm.nih.gov/12507206/
105. (2015). Diverting ileostomy versus no diversion after low anterior resection for rectal cancer: A prospective, randomized, multicenter trial. Journal of the American College of Surgeons 221. https://pubmed.ncbi.nlm.nih.gov/26706610/
106. (2025). Rectal Cancer. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®). https://www2.tri-kobe.org/nccn/guideline/colorectal/english/rectal.pdf
107. (2013). Prognosis of rectal cancer patients improves with downstaging by intensified neoadjuvant radiochemotherapy - a matched pair analysis. BMC Cancer 13. https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-13-388
108. (2020). Effect of adjuvant chemotherapy on the oncological outcome of rectal cancer patients with pathological complete response. World Journal of Surgical Oncology 18. https://wjso.biomedcentral.com/articles/10.1186/s12957-024-03300-0
109. (2020). Neoadjuvant radiotherapy improves overall survival for T3/4N+M0 rectal cancer patients: a population-based study of 20,300 patients. Radiation Oncology 15. https://ro-journal.biomedcentral.com/articles/10.1186/s13014-020-01497-4
110. (2023). Effect of interval between neoadjuvant chemoradiotherapy and surgery on disease recurrence and survival in rectal cancer: long-term results of a randomized clinical trial. BJS Open 6. https://academic.oup.com/bjsopen/article/6/5/zrac107/6762515
111. (2024). The 'Watch and wait' approach following neoadjuvant therapy for rectal cancer. Annali Italiani di Chirurgia 95. https://annaliitalianidichirurgia.it/index.php/aic/article/download/2944/2699/5282
112. (2021). A meta-analysis of the watch-and-wait strategy versus total mesorectal excision for rectal cancer exhibiting complete clinical response after neoadjuvant chemoradiotherapy. World Journal of Surgical Oncology 19. https://wjso.biomedcentral.com/articles/10.1186/s12957-021-02415-y
113. (2023). Pelvic Radiation Therapy Avoided for Most Patients With Intermediate-Risk, Locally Advanced Rectal Cancer. https://ascopost.com/issues/july-10-2023/pelvic-radiation-therapy-avoided-for-most-patients-with-intermediate-risk-locally-advanced-rectal-cancer/
114. Bosset, Jean-François & al., e. (2014). No Survival Benefit of Adjuvant 5-FU–Based Chemotherapy After Neoadjuvant Radiotherapy or Chemoradiation for Resectable Rectal Cancer. The Lancet Oncology 15. https://ascopost.com/News/12901
115. (2023). NCCN Guidelines®: Colon Cancer. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon Cancer, Version 1.2024. https://www.oregon.gov/oha/HPA/DSI-HERC/MembersOnly/NCCN%201.2024%20colon.pdf
116. (n.d.). What is the FOLFIRI chemo regimen and how does it work?. www.drugs.com. https://www.drugs.com/medical-answers/what-folfiri-chemo-regimen-how-work-3579914/
117. (2004). Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer. New England Journal of Medicine 350. https://pubmed.ncbi.nlm.nih.gov/17145525/
118. (2023). FOLFIRI + Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer. Oncology Times 45. https://journals.lww.com/oncology-times/fulltext/2023/02200/folfiri___cetuximab_for_ras_wild_type_metastatic.14.aspx
119. Satake & al., H. e. (2018). A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11. Oncotarget 9. https://pubmed.ncbi.nlm.nih.gov/29721163/
120. (2017). Bayer Receives EU Approval for Stivarga® (Regorafenib) for the Second-Line Systemic Treatment of Liver Cancer. Bayer.com. https://www.bayer.com/media/en-us/bayer-receives-eu-approval-for-stivargar-regorafenib-for-the-second-line-systemic-treatment-of-liver-cancer/
121. (2024). Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer. Invest New Drugs 42. https://pubmed.ncbi.nlm.nih.gov/38990451/
122. (2021). Second-Line Treatment Strategies for Right-Sided, RAS/RAF Wild-Type Colorectal Cancer. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2835231
123. (2025). Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer. https://pubmed.ncbi.nlm.nih.gov/40444708/
124. (2023). Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study. https://pubmed.ncbi.nlm.nih.gov/37751561/
125. (2025). FDA D.I.S.C.O.: FDA approval of larotrectinib for advanced malignancies with NTRK gene fusion. FDA. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-fda-approval-larotrectinib-advanced-malignancies-ntrk-gene-fusion
126. (2025). Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. Journal of Clinical Oncology 43. https://pubmed.ncbi.nlm.nih.gov/31725351/
127. Li & al., J. e. (2022). Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis. BMC Gastroenterology 22. https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-022-02511-7
128. (2022). Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis. https://wjso.biomedcentral.com/articles/10.1186/s12957-022-02549-7
129. (2025). FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer. FDA. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer
130. (2025). Role of Neoadjuvant Immune Checkpoint Inhibitors in Colorectal Cancer. https://journals.lww.com/dcrjournal/fulltext/2025/11000/role_of_neoadjuvant_immune_checkpoint_inhibitors.9.aspx
131. (2025). Nivolumab plus ipilimumab sets new standard of care in MSI-H/dMMR mCRC. International Journal of Oncology 66. https://www.targetedonc.com/view/nivolumab-plus-ipilimumab-sets-new-standard-of-care-in-msi-h-dmmr-mcrc
132.  (2023). Results of three investigator-initiated trials on cadonilimab (PD-1/CTLA-4) for G/GEJC, pMMR/MSS mCRC, and HCC neoadjuvant therapy published at ESMO Asia 2023. https://www.prnewswire.com/news-releases/results-of-three-investigator-initiated-trials-on-cadonilimab-pd-1ctla-4-for-ggejc-pmmrmss-mcrc-and-hcc-neoadjuvant-therapy-published-at-esmo-asia-2023-302005825.html
133. (2004). Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Annals of Surgical Oncology 11. https://pubmed.ncbi.nlm.nih.gov/15319715/
134. (1997). Prognostic factors and survival after complete resection of pulmonary metastases from colorectal carcinoma: experiences in 167 patients. Journal of Thoracic and Cardiovascular Surgery 113. https://pubmed.ncbi.nlm.nih.gov/14502146/
135. Wasif, Curtis, N., Halfdanarson, K. K., Grotz, T. R. & E., T. (2018). Cytoreductive surgery and HIPEC offers effective treatment for selected patients with peritoneal carcinomatosis. Mayo Clinic Proceedings 93. https://www.mayoclinic.org/medical-professionals/cancer/news/cytoreductive-surgery-and-hipec-offers-effective-treatment-for-selected-patients-with-peritoneal-carcinomatosis/mac-20429726
136. (2023). Conversion Surgery for Initially Unresectable Stage ? Nonsmall Cell Lung Cancer After Induction Treatment of Immunochemotherapy: A Multicenter Study. Journal of Thoracic Oncology 18. https://pubmed.ncbi.nlm.nih.gov/39848828/
137. Falcone, A., Ricci, S., Brunetti, I., Loupakis, F., Masi, G., Tosi, F., Labianca, .. &. & R. (2007). FOLFOXIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer: the TRIBE trial. Annals of Oncology 18. https://pubmed.ncbi.nlm.nih.gov/28542671/
138. (2025). Stereotactic body radiation therapy in non-liver colorectal metastases: a scoping review. https://jgo.amegroups.org/article/view/78235/html
139. (2021). ACG Clinical Guidelines: Colorectal Cancer Screening 2021. American Journal of Gastroenterology 116. https://journals.lww.com/ajg/fulltext/2021/03000/acg_clinical_guidelines__colorectal_cancer.14.aspx
140. (2021). Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial. https://jamanetwork.com/journals/jamaoncology/fullarticle/2780033
141. (2020). Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2020. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. https://pubmed.ncbi.nlm.nih.gov/32259849/
142. (2016). Recommendations for the Care of Individuals With an Inherited Predisposition to Lynch Syndrome: A Systematic Review. JAMA 315. https://jamanetwork.com/journals/jama/fullarticle/203403
143. (2025). Familial Adenomatous Polyposis (FAP): Symptoms, Diagnosis, Risks. Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/16993-familial-adenomatous-polyposis-fap
144. (2025). Monitoring for Colorectal Cancer Recurrences. colorectalcancer.org. https://colorectalcancer.org/treatment/you/survivors/monitoring-colorectal-cancer-recurrences
145. (2025). NCCN Guidelines for Colon Cancer. National Comprehensive Cancer Network (NCCN) Colon Cancer Guidelines. https://www2.tri-kobe.org/nccn/guideline/colorectal/english/colon.pdf
146. (2025). Colorectal Cancer (Version 4.2025). National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®). https://www2.tri-kobe.org/nccn/guideline/colorectal/english/rectal.pdf
147. (2006). Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 130. https://pubmed.ncbi.nlm.nih.gov/16697749/
148. (2016). Colonoscopy Surveillance After Colorectal Cancer Resection. Gastroenterology 150. https://doi.org/10.1053/j.gastro.2016.01.001
149. (2008). Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. https://pubmed.ncbi.nlm.nih.gov/18441865/
150. (n.d.). Resection of recurrent liver cancer - Surgical Treatment. National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/books/NBK6910/
151. (2024). Prognostic significance of negative lymph node count in microsatellite instability-high colorectal cancer. World Journal of Surgical Oncology 22. https://wjso.biomedcentral.com/articles/10.1186/s12957-024-03469-4
152. (2023). BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy. Journal of Gastrointestinal Oncology 8. https://academic.oup.com/gastro/article/8/3/192/5857791
153. (2019). Quality of Life and Patient-Reported Outcomes in Cancer. University of Wisconsin Carbone Cancer Center. https://cancer.wisc.edu/research/wp-content/uploads/2019/05/Quality-of-Life-and-Pt-Reported-Outcomes.pdf
154. (2023). A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study. Journal of Clinical Oncology 41. https://pubmed.ncbi.nlm.nih.gov/36638198/
155. (2024). ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors. Daiichi Sankyo US. https://daiichisankyo.us/press-releases/-/article/enhertu-approved-in-the-u-s-as-first-tumor-agnostic-her2-directed-therapy-for-previously-treated-patients-with-metastatic-her2-positive-solid-tumors
156. Lakkakula, B.V.K.S., Farran, B., Lakkakula, S., Peela, S., Yarla, N.S., Bramhachari, P.V., Kamal, M.A., Saddala, M.S., Nagaraju & G.P. (2021). The development of multi-kinase inhibitors as pancreatic cancer therapeutics. Pancreatic Cancer 27. https://pubmed.ncbi.nlm.nih.gov/34397447/
157. (2024). Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver. International Journal of Molecular Sciences 25. https://www.mdpi.com/1422-0067/25/6/1500
158. Petrelli, Ghidini, F., Ghidini, M., Tomasello, A. & Gianluca. (2025). Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers: A Systematic Review and Meta-analysis. JAMA Oncology 11. https://jamanetwork.com/journals/jamaoncology/fullarticle/2765752
159. (2024). Circulating Tumor DNA Levels Predict Treatment Outcomes for Patients with Gastroesophageal Cancer Treated with a Novel Immunotherapy Combination. Johns Hopkins Medicine. https://www.hopkinsmedicine.org/news/newsroom/news-releases/2024/03/circulating-tumor-dna-levels-predict-treatment-outcomes-for-patients-with-gastroesophageal-cancer-treated-with-a-novel-immunotherapy-combination
160. (2024). Liquid biopsy Circulating tumor DNA Circulating tumor cells. Journal of Liquid Biopsy 3. https://air.uniud.it/retrieve/4f90a2bf-ddd1-4be9-81b6-cb8d87e305e0/PIIS2950195423001327.pdf
161. White, T., M., Sears & L., C. (2023). The microbial landscape of colorectal cancer. Nature Reviews Microbiology 21. https://pubmed.ncbi.nlm.nih.gov/37794172/
162. (2024). Physical Activity and Cancer. Centers for Disease Control and Prevention. https://www.cdc.gov/physical-activity-basics/health-benefits/lowers-risk-of-cancer.html
163. (2023). Limit consumption of red and processed meat. World Cancer Research Fund. https://www.wcrf.org/research-policy/evidence-for-our-recommendations/limit-red-processed-meat/
164. (2025). Deciphering the Impact of Dietary Habits and Nutritional Factors on Colorectal Cancer Risk. https://journals.lww.com/international-journal-of-surgery/fulltext/2025/03000/deciphering_the_impact_of_dietary_habits_and.25.aspx
165. (2013). Dose–Risk and Duration–Risk Relationships between Aspirin and Colorectal Cancer: A Meta-Analysis of Published Cohort Studies. Journal of Clinical Oncology 31. https://pubmed.ncbi.nlm.nih.gov/23451245/
166. (2007). Routine Aspirin or NSAIDs for Primary Prevention of Colorectal Cancer. Annals of Internal Medicine, Vol. 146, Issue 5, pp. 365-368. https://www.uspreventiveservicestaskforce.org/home/getfilebytoken/c-7ARQE9RuXKjjpeLABkaH
167. (2021). Systematic Review and Meta-Analysis of the Association Between Metformin Use and Cancer Risk and Survival Outcomes in Patients with Type 2 Diabetes Mellitus. Frontiers in Endocrinology 10. https://www.frontiersin.org/articles/10.3389/fendo.2019.00617/full
168. (2024). FIT Screening Significantly Reduces Colorectal Cancer Risk. https://medschool.kp.org/news/fit-screening-significantly-reduces-colorectal-cancer-risk
169. Løberg & al., M. e. (2014). Long-Term Colorectal Cancer Mortality After Removal of Adenomas. The New England Journal of Medicine 371. https://www.nejm.org/doi/full/10.1056/NEJMoa1401854